Trial Profile
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Hydroxychloroquine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 29 Mar 2022 Status changed from active, no longer recruiting to completed.
- 31 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Dec 2021.
- 31 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.